BRIEF—Celgene and Takeda invest in Presage, which also names new CEO

US oncology-focussed biotech Presage Biosciences today announced that it has closed a Series D financing led by pharmaceutical companies Takeda and Celgene.

Both Celgene and Takeda have made previous investments in Presage.

The company also announced that Dr Richard Klinghoffer, currently Presage's chief scientific officer, has been named chief executive.

Dr Klinghoffer will take over CEO responsibilities from Nathan Caffo, who will continue to advise the company on business and strategic matters as senior corporate advisor.

Dave Johnson, chairman of the board, said: "We are thrilled to have closed this financing with long-time Presage strategic partners, Takeda and Celgene. This $6 million investment brings the total equity raised by Presage to $26 million and comes at an important time for Presage as we aim to broaden the use of the CIVO platform in clinical intratumoral microdosing studies with a range of biopharma partners."